Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $1.56 million for the quarter.
Armata Pharmaceuticals Stock Up 4.6 %
NYSEAMERICAN:ARMP opened at $2.04 on Tuesday. The firm has a market capitalization of $73.81 million, a P/E ratio of -1.24 and a beta of 0.87. Armata Pharmaceuticals has a 12-month low of $1.80 and a 12-month high of $4.25.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Stories
- Five stocks we like better than Armata Pharmaceuticals
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Can TikTok Stock Picks Really Make You Rich?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- The “Quality” Rotation: Back to Basics Investing
- Are Penny Stocks a Good Fit for Your Portfolio?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
